AstraZeneca Pharma India Limited (ASTRAZEN) AI Stock Analysis

• Market Cap: ₹226.24B
• Dividend Yield: 0.35%
• Average Volume (3M): 602.00
• Price to Earnings (P/E): 113.6
• Beta (1Y): 0.73
• Revenue Growth: 35.14%
• EPS Growth: 143.11%
• Country: IN
• Employees: 940
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 21.69
• Shares Outstanding: 25,000,000
• 10 Day Avg. Volume: 682
• 30 Day Avg. Volume: 602
• PEG Ratio: -6.48
• Price to Book (P/B): 27.56
• Price to Sales (P/S): 12.37
• P/FCF Ratio: 333.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 70 Outperform
• Price Target: ₹9,775.00 ▲(8.91% Upside)

AstraZeneca Pharma India Limited's strong financial performance, characterized by consistent revenue growth and solid cash flow management, is the primary driver of its stock score. However, the high P/E ratio suggests the stock may be overvalued, which, along with neutral technical indicators, tempers the overall score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective business strategies, enhancing long-term financial stability.

Cash Flow Management

Strong cash flow management ensures the company can fund operations and investments, supporting sustainable growth and resilience.

Balance Sheet Health

Low financial leverage indicates a strong balance sheet, providing financial flexibility and reducing risk in economic downturns.

Negative Factors

Net Profit Margin Decline

A declining net profit margin suggests rising costs or pricing pressures, which could impact profitability if not addressed.

Return on Equity Decline

A declining ROE indicates less efficient use of equity capital, potentially affecting investor confidence and future capital raising.

Increasing Liabilities

Rising liabilities could strain financial resources, requiring careful management to avoid impacting long-term financial health.

AstraZeneca Pharma India Limited Business Overview & Revenue Model

Company Description

AstraZeneca Pharma India Limited (ASTRAZEN) is a leading biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. Operating primarily in the therapeutic areas of oncology, cardiovascular, renal, respiratory, and inflammation, AstraZeneca India is committed to delivering innovative healthcare solutions. The company offers a range of pharmaceutical products, including branded and generic drugs, while also engaging in research collaborations and partnerships to enhance its product offerings.

How the Company Makes Money

AstraZeneca Pharma India Limited generates revenue primarily through the sale of its pharmaceutical products, which encompass a diverse portfolio of medicines across various therapeutic areas. The company's revenue model is based on direct sales to healthcare providers, hospitals, and pharmacies, as well as through contracts with government health programs. Key revenue streams include the sale of patented drugs, which provide higher profit margins, as well as revenue from generic medicines. Significant partnerships with healthcare organizations, other pharmaceutical companies, and research institutions further bolster its earnings through collaborative research and development initiatives, licensing agreements, and co-marketing arrangements. Additionally, AstraZeneca's investment in marketing and sales strategies helps to maintain and grow its market share in the competitive pharmaceutical landscape.

AstraZeneca Pharma India Limited Financial Statement Overview

Summary

AstraZeneca Pharma India Limited demonstrates robust financial health with consistent revenue growth and strong cash flow management. The company maintains a stable balance sheet with minimal leverage and a solid equity base. Despite a decrease in net profit margins and return on equity in recent years, the overall financial performance remains commendable, driven by strong operating efficiencies and cash generation capabilities.

Income Statement

AstraZeneca Pharma India Limited has demonstrated a strong revenue growth trajectory with a notable increase in Total Revenue from ₹8,056 million in 2022 to ₹17,162 million in 2025, marking consistent annual growth. The Gross Profit Margin remains robust, improving from 55.6% in 2022 to 43.9% in 2025. EBIT and EBITDA Margins are stable with EBIT Margin at 12.5% and EBITDA Margin at 11.5% in 2025, highlighting operational efficiency. However, the Net Profit Margin decreased from 12.3% in 2024 to 6.7% in 2025 due to rising operational costs.

Balance Sheet

The company maintains a strong equity base with Stockholders' Equity increasing from ₹5,113.9 million in 2022 to ₹7,703.5 million in 2025. The Debt-to-Equity Ratio is low at 0.05 in 2025, indicating low financial leverage. The Equity Ratio improved to 50.7% in 2025, reflecting a stable financial position. However, Total Liabilities have increased over time, which could pose a risk if not managed properly. Return on Equity (ROE) decreased from 22.7% in 2022 to 15.0% in 2025, requiring attention.

Cash Flow

The company exhibits strong cash flow management, with Free Cash Flow growing significantly from ₹911.8 million in 2022 to ₹636.1 million in 2025. The Operating Cash Flow to Net Income Ratio improved to 0.56 in 2025, indicating efficient conversion of income into cash. The company's ability to generate sufficient cash flow to cover its capital expenditures and operating needs is a positive financial indicator.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	18.55B	17.16B	12.96B	10.03B	8.06B	8.09B
Gross Profit	8.27B	7.53B	6.22B	5.78B	4.48B	4.78B
EBITDA	3.01B	1.98B	2.36B	1.51B	1.01B	1.48B
Net Income	1.83B	1.16B	1.62B	992.90M	616.00M	933.00M
Balance Sheet
Total Assets	0.00	15.18B	10.78B	9.85B	8.57B	7.75B
Cash, Cash Equivalents and Short-Term Investments	5.36B	5.53B	5.06B	5.00B	4.48B	3.52B
Total Debt	0.00	357.30M	45.90M	72.14M	86.30M	121.40M
Total Liabilities	-7.70B	7.48B	3.66B	3.96B	3.45B	3.19B
Stockholders Equity	7.70B	7.70B	7.12B	5.89B	5.11B	4.56B
Cash Flow
Free Cash Flow	0.00	636.10M	171.10M	497.70M	911.80M	970.70M
Operating Cash Flow	0.00	653.60M	278.70M	582.90M	1.01B	1.05B
Investing Cash Flow	0.00	308.00M	217.40M	181.10M	47.40M	1.73B
Financing Cash Flow	0.00	-655.90M	-443.80M	-244.80M	-94.60M	-89.70M

AstraZeneca Pharma India Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 8975.70
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTRAZEN, the sentiment is Neutral. The current price of 8975.7 is below the 20-day moving average (MA) of 9181.38, below the 50-day MA of 9172.65, and above the 200-day MA of 8653.79, indicating a neutral trend. The MACD of -57.12 indicates Positive momentum. The RSI at 45.46 is Neutral, neither overbought nor oversold. The STOCH value of 25.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:ASTRAZEN.

AstraZeneca Pharma India Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALKEM	72 Outperform	₹677.34B	29.65	―	0.79%	9.32%	11.25%
ASTRAZEN	70 Outperform	₹226.24B	113.60	―	0.35%	35.14%	143.11%
GLAXO	63 Neutral	₹450.87B	47.45	―	2.10%	4.17%	41.51%
GLENMARK	53 Neutral	₹521.13B	69.14	―	0.26%	30.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

AstraZeneca Pharma India Limited Corporate Events

AstraZeneca Pharma India Gains Approval for New Cancer Treatment Indication

AstraZeneca Pharma India Limited has announced that it received approval from the Central Drugs Standard Control Organisation to import and market Trastuzumab Deruxtecan (Enhertu) for a new indication in India. This approval allows the company to provide treatment for adult patients with unresectable or metastatic HER2-positive solid tumors who have previously undergone systemic treatment and lack satisfactory alternative options, potentially enhancing the company’s market presence in oncology.